PROVASTATIN

Provastatin (likely Pravastatin variant) inhibits HMGCoA reductase, reducing LDL levels and cardiovascular risk. Side effects include muscle pain, elevated liver enzymes, nausea, and rare rhabdomyolysis. Only GMP materials will be supplied, logistics all according to GDP.

SKU: e74a09a74e7e Category: Tag:

Product Description


Mechanism of Action

PROVASTATIN demonstrates a highcomplexity biochemical interaction profile characterised by multilayer signalling integration, modular enzymatic pathway penetration, mitochondrial network modulation, ionflux recalibration, redoxstate equilibrium restructuring and transcriptionfactor axis reprogramming. Its molecular geometry enables conformational docking to catalytic pockets, allosteric domains, transmembrane receptor helices and cytoskeletal scaffolds, creating broad regulatory influence across metabolic, structural and genomic systems.

At the signalling level, PROVASTATIN may modulate phosphorylation gradients, kinome cascade propagation (including MAPK, JNK, ERK, PI3KAKT, and AMPK axes), Gprotein subunit turnover, calcium wave propagation, secondary messenger amplification and stressadaptation thresholds. Mitochondrially, the compound can alter electrontransportchain efficiency, ATPADP cycling, mitochondrial ROS leakage, membrane potential polarity and respiratorycomplex activation ratios.

Advanced Research Value

PROVASTATIN is particularly suited for:

  • Crosspathway interference mapping and kinome interaction grids
  • Ultrahigh resolution receptorligand docking and conformational prediction
  • Organellestress modelling (ER stress, mitochondrial folding stress, autophagic flux modulation)
  • Networklevel transcriptome rewiring using multiomics clustering
  • Precision cytoskeletalmechanics analysis including actin polymerisation and tubulin turnover
  • Apoptotic vs. survivalpathway bias quantification
  • Advanced SAR, QSAR and machinelearning molecularperformance modelling

Risks, Toxicodynamics & Cellular Hazard Spectrum

At elevated exposure levels, PROVASTATIN may induce:

  • ROS surge and oxidative collapse
  • Mitochondrial hyperfragmentation or respiratorycomplex shutdown
  • Severe ionchannel destabilisation
  • Cytoskeletal disassembly and membrane-integrity breach
  • Aberrant transcriptionfactor activation, inflammatory bursts (NF-κB, STAT, IRF pathways)
  • Highgrade apoptosis, necroptosis or ferroptosis initiation
  • Epigenetic instability affecting methylation/acetylation balance

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C23H35NO5

Molecular Weight

424.52 g/mol

CAS Number

81131-70-6

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

6-EPI PRAVASTATIN, SODIUM SALT; C23H35NaO7; NCGC00095183-01; Pravastatin-d3 sodium (major); CHEMBL1317360

IUPAC/Chemical Name

(3R,5R)-7-{(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download